As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >


Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >


Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >

A two-drug combination to treat limb-girdle muscular dystrophies and cystic fibrosis

The I-Stem and Genethon laboratories have identified a promising drug combination in the setting of three genetic diseases sharing similar molecular mechanisms.
Image de cellules par imagerie issue de l'étude de la combinaison de 2 médicaments pour le traitement de la mucoviscidose et des myopathies Image de cellules par imagerie issue de l'étude de la combinaison de 2 médicaments pour le traitement de la mucoviscidose et des myopathies

Xavier Nissan’s muscular dystrophies pharmacology team at I-Stem, in partnership with Isabelle Richard from Généthon and the company Kantify, has identified a pharmacological combination conferring a novel mode of action potentially efficacious against not only limb-girdle muscular dystrophy types R3s and R5 but also cystic fibrosis. The discovery was made possible by marrying competencies and knowledge in cellular models for disease, high throughput drug screening, myopathy mechanisms and artificial intelligence.

Limb-girdle muscular dystrophy (LGMD) type R3, like the 30 some-odd other types of the disease, presents as progressive weakening of mostly the hip and shoulder muscles. This particular type is caused by mutations in alpha-sarcoglycan, a protein within the dystrophin glycoprotein complex, itself an element within the membrane of striated muscle that protects this latter from contraction-induced damage. The mutation most frequently associated with the disease, called R77C, involves an amino acid substitution resulting in abnormal folding of α-sarcoglycan. Once identified by a cellular quality control mechanism, the misfolded protein is broken down by proteasomes, one of the cell’s many organelles.

Researchers from two of Genopole’s laboratories, I-Stem and Genethon (AFM-Téléthon, Inserm, University of Evry Paris-Saclay) teamed to identify drugs capable of inhibiting that breakdown, because even misfolded, α-sarcoglycan does remain partially functional. They thus developed a cellular model of the disease from patient fibroblasts and thereafter tested 958 drugs already approved by the American Food and Drug Administration for other indications. This exploration of drugs approved for other uses, called drug repositioning, offers many advantages, including the possibility of getting treatments to patients faster. The pharmaceutical compounds were tested alone or in combination with a low dose of bortezomib, a molecule known to inhibit the proteasome but also associated with cytotoxic effects at efficacious doses. Thus, the objective of the team’s approach was to confer protection for the muted α-sarcoglycan while minimizing the cytotoxic effects of bortezomib. In the study, the researchers performed an ADMET (absorption, distribution, metabolism, elimination and toxicity) analysis via an artificial intelligence developed by Kantify and trained for assay results prediction on 150,000 compounds. That AI analysis considered 76 ADMET endpoints and ranked the retained molecules in terms of benefit-risk, thus indicating their potential for successful clinical development.

The work by the Évry team led to the identification of 47 possibly-therapeutic compounds. Among them, givinostat in particular showed a strong ability to restore the expression of mutant cell-membrane α-sarcoglycan. Indeed, givinotat is currently in phase III trials for Duchenne muscular dystrophy and showing promising preliminary results. Givinostat appears to inhibit the cell’s autophagic pathway, a system complementary to the proteasome for ensuring the elimination of abnormal proteins.

Thus, beyond the identification of givinostat + bortezomib as a promising combination against LGMD type R3, the I-Stem/Genethon study published in Frontiers in Pharmacology on 27 April 2022, also shed light on the double, autophagic and proteasomic, mechanism involved in the degradation of the misfolded protein. That discovery led the team to extend its study to two diseases with similar protein-breakdown aspects: LGMD type R5 and cystic fibrosis, on which the givinostat + bortezomib combination also showed positive effects.

Toward new treatments for rare genetic diseases?

Such approaches, wherein rare genetic diseases (most of which remain incurable) are considered in terms of groups of diseases sharing molecular mechanisms, is revolutionizing drug discovery.

Study schema ⬇️

Schéma de synthèse de l’étude de la combinaison de médicaments pour le traitement des myopathies et de la mucoviscidose
The screening of 958 compounds on a cellular model of limb-girdle muscular dystrophy type R3 (LGMDR3) and an ADMET artificial intelligence analysis identified givinostat as the primary compound of interest, studied thereafter for its mode of action. The combination of givinostat and bortezomib was shown to have potential therapeutic effect not only for LGMDR3, but also for LGMDR5 and cystic fibrosis.


This study by the I-Stem/Genethon team illustrates the potential of Genopole’s actors for the development of innovative therapies.


Dual Blockade of Misfolded Alpha-Sarcoglycan Degradation by Bortezomib and Givinostat Combination.

Frontiers in Pharmacology, 2022

Press Release

Article posted on 18 May 2022


Latest news

©Lionel Antoni - Plateforme d'irradiation expérimentale du LRGK - Plateforme génopolitaine mutualisée avec les acteurs de la communauté scientifique francilienne

The Experimental Irradiation Platform to serve the Île-de-France scientific community

Genopole is making available to the Île-de-France scientific community an Experimental Irradiation Platform equipped with a state of the art generator

Laina Freyer directrice scientifique, Felome

Felome Launches the Commercialization of Genetic Analyses for Companion Cats

Felome will begin the commercialization of a service offering genetic analyses for companion cats, to reveal their predispositions to over 50 diseases, identify their main physical traits, and their similarities with 14 types of breeds.

Lauréats de la promo 3 du programme Gene.iO - Genopole

Three Gene.iO whiz kids rewarded for their innovations

Three Gene.iO whiz kids, Alga Biologics, Fungu'it and Alt Biotech, rewarded for their innovations. Alga Biologics was among the 35 start-ups included in the French Blue Tech Index. Fungu'it and Alt Biotech, were selected to participate in 212 Founders, a start-up accompaniment and financing program by CDG Invest.

l'équipe iGEM 2023 Evry Paris-Saclay - Médaille d'or et p

A prize and gold for the 2023 Évry Paris-Saclay iGEM team

The international synthetic biology competition iGEM celebrated its 20th anniversary. From across the globe, the event drew more than 7,000 students in 400 teams from 66 countries. Genopole was there, among other actors in synthetic biology, to present the biocluster's advantages at its stand, and support the 17 students of the Évry Paris-Saclay team and their outstanding project, OptoGenEYEsis.

Genopole en mission exploratoire au Japon et en Corée du sud - octobre 2023

An exploratory mission to Japan and South Korea for Genopole

Genopole sent a team to Japan and South Korea to present itself and several of its accompanied businesses to major pharmaceutical corporations, investors and Asian bioclusters curious about biotechnological innovations and open to international partnerships.

Ibisc - Genopole's Laboratory

IBISC – Structure prediction for RNA complexes

passes a milestone in structure prediction for RNA complexes, key players in cell biology.

IBISC: A first predictive tool for the emerging field of bifunctional RNA

IBISC: A first predictive tool for the emerging field of bifunctional RNA

The IBISC laboratory has developed IRSOM2, an unprecedented bioinformatics tool for the prediction of bifunctional RNA, a relatively recently discovered class of RNA showing both an ability to code for proteins and an ability to perform biological roles.

Integrating informatics, structural biology and in vivo exploration for the discovery of new medicines

SABNP & Synsight: discovery of new medicines

SABNP and Synsight have validated an integrated, drug discovery approach uniting informatics, structural biology and in vivo exploration.

Alexis Biton and Paul Carouen - Genopole - visiting the Research Triangle Park (USA) accompanied by 3 Genopole's companies

Genopole strengthens its ties with the Research Triangle Park

From Monday March 20 to Thursday March 24, Genopole's Partnership & Business Development team visited the Research Triangle Park biopark in North Carolina to strengthen scientific and industrial collaborations.

Lambe - Genopole's laboratory

Lambe: Detecting coagulation biomarkers with a natural nanopore

The Lambe laboratory showed proof of concept for a coagulation biomarker detection technology based on a natural nanopore.

Andrew Tolonen's team within the unit of Genomics Metabolics (Genoscope - CEA)

Genoscope: Biomanufacturing with bacteria

A team led by Andrew Tolonen has developed a method to optimize the genetic engineering of Clostridium genus bacteria for biotech applications

l’équipe « Dystrophies musculaires progressives » du laboratoire Généthon

Shining light on a key mechanism of Duchenne muscular dystrophy

A Genethon team has provided new insights on a complex genetic mechanism involved in mitochondrial dysfunction in Duchenne muscular dystrophy.

A trio of genome sites associated with arterial hypertension

A trio of genome sites associated with arterial hypertension

Researchers from the CNRGH and PARCC have identified three loci associated with an increased risk of developing primary hyperaldosteronism, a leading cause of arterial hypertension.

Genoscope - CNS - Genopole's laboratory

The story of the domestic donkey told by its genome

Genoscope participated in the sequencing of the DNA of 250 donkeys in a study revealing the domestication of this species highly contributive to human activities to this day.

Galaxy-SynBioCAD: accelerating the arrival of green chemistry

Galaxy-SynBioCAD: accelerating the arrival of green chemistry

Conceived by the Genomics Metabolics Unit, Galaxy-SynBioCAD accelerates biological design and engineering for the production of next generation chemical compounds.

Equipe Sysfate de l'UMR 8030 - projet T-Fitness

T-FITNESS: Toward empowering CAR-T therapies for solid tumors

The Genopole team SysFate is participating in the international project T-FITNESS. The project, selected by the European Innovation Council, aims to resolve the difficulty of T-cell exhaustion in CAR-T therapies for solid tumors.

Ynsect & Genoscope : Vers la sélection génomique des insectes d’élevage

Toward the genomic selection of farmed insects

France is historically a land of livestock farming. Cows for meat or milk, sheep, pigs, fowl of all sorts; France rears them all. And insects! With its genomic selection project for Tenebrio molitor beetles, the Genopole company Ÿnsect and its biocluster partner, the sequencing center Genoscope, are making France a pioneer in insect farming.

Couverture de la revue Cell Genomics - Le plancton

A feat in the study of planktonic life

A Genoscope research team was part of a pioneering study in environmental genomics. The researchers were able to at least partially reconstitute the genomes of close to 700 eukaryote species.

IBISC - IA qui diagnostique et explique grâce à un réseau de neurones

An artificial intelligence to diagnose and explain

The IBISC laboratory has conceived an architecturally-innovative neural network able to provide not only a diagnostic prediction but also a biological explanation.

Christophe Lanneau - Research & Platforms Department Director

News from the human genome

The 1 April edition of Science announced the publication of the human genome with the previously-missing 8% now added to it. Comments from the Genopole Director of Research.

View all >
With the support from
Région île de France